Using targeted radiation therapy to treat metastatic cancer
Official title: Imaging, Dosimetry and Radiobiology for α-particle Emitter Radiopharmaceutical Therapy
Funded at Johns Hopkins University · NIH-10931426 · Data updated 2026-11-12
This study is testing a new way to treat metastatic cancer using a special type of radiation that targets cancer cells while protecting healthy ones, and it aims to find the safest amount of radiation for each patient to improve their treatment experience and results.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | September 19, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $2,450,276 |
| NIH project number | 5P01CA272222-02 |
| Project ID | NIH-10931426 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic cancer who have not responded well to traditional therapies.
✕Less likely to help
Patients with localized cancer or those who are not eligible for radiopharmaceutical therapy may not benefit from this research.
What this research studies
This research focuses on developing a new treatment for metastatic cancer using alpha-particle-emitting radiopharmaceutical therapy (αRPT). It aims to deliver radiation directly to cancer cells while minimizing damage to healthy tissue, addressing the challenges of treatment-induced toxicity. The study will create and validate dosimetry methods to better predict how much radiation can be safely administered to patients, allowing for more personalized treatment plans. By improving the precision of this therapy, the research seeks to enhance treatment efficacy and patient outcomes.
Why it matters
Potential benefit: If successful, this research could provide a safer and more effective treatment option for patients with metastatic cancer.
How similar studies have gone: Previous research has shown promise in using targeted radiation therapies, but this specific approach with αRPT is relatively novel and untested.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Sgouros, George — Johns Hopkins University
- Study coordinator: Sgouros, George
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.